Get the Stockscreener App
2.68
4.28%
0.11
After Hours:
2.75
0.07
+2.61%
Iovance Biotherapeutics Inc stock is traded at $2.68, with a volume of 16.63M.
It is up +4.28% in the last 24 hours and up +54.02% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$2.57
Open:
$2.5
24h Volume:
16.63M
Relative Volume:
1.00
Market Cap:
$894.94M
Revenue:
$32.77M
Net Income/Loss:
$-440.22M
P/E Ratio:
-1.6048
EPS:
-1.67
Net Cash Flow:
$-400.48M
1W Performance:
-14.38%
1M Performance:
+54.02%
6M Performance:
-54.19%
1Y Performance:
-67.16%
1-Day Range:
$2.45
$2.71
1-Week Range:
$2.45
$3.41
52-Week Range:
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.68 | 858.21M | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
| May-16-25 | Downgrade | UBS | Buy → Neutral |
| May-12-25 | Downgrade | Truist | Buy → Hold |
| May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
Is Iovance Biotherapeutics Inc. stock overvalued or undervaluedMarket-leading growth rates - jammulinksnews.com
What are Iovance Biotherapeutics Inc. company’s key revenue driversMassive wealth growth - jammulinksnews.com
Will Iovance Biotherapeutics Inc. price bounce be sustainableFree Early Entry Picks Before News Breakout - Newser
What institutional investors are buying Iovance Biotherapeutics Inc. stockAchieve consistent profits with proven strategies - jammulinksnews.com
What are the latest earnings results for Iovance Biotherapeutics Inc.Invest smarter with actionable trading signals - jammulinksnews.com
What is the dividend policy of Iovance Biotherapeutics Inc. stockStock Market Picks With High Returns - jammulinksnews.com
A Closer Look at Iovance Biotherapeutics Inc (IOVA) Stock Gains - investchronicle.com
Iovance Biotherapeutics: Unlocking TIL Therapy's Potential Amid Funding Challenges - AInvest
Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges - Yahoo Finance
Day 6 of Loss Streak for Iovance Biotherapeutics Stock with -35% Return (vs. -65% YTD) [7/31/2025] - Trefis
Iovance Biotherapeutics (IOVA) Gets Downgraded to Sell from Neutral at Goldman Sachs - MSN
Intraday pattern recognizer results for Iovance Biotherapeutics Inc.Real-Time Setup Summary with ROI Focus - Newser
Iovance Biotherapeutics: Recent Clinical Study Results and Leadership Appointments Boost Growth Prospects - AInvest
Iovance Biotherapeutics shares rise 4.12% premarket after Eisai and Biogen's Alzheimer's drug LEQEMBI shows sustained long-term benefits. - AInvest
Exit strategy if you’re trapped in Iovance Biotherapeutics Inc.Chart Driven Entry Timing for Swing Trades - Newser
What is the risk reward ratio of investing in Iovance Biotherapeutics Inc. stockEarnings Report Planner For 2025 - jammulinksnews.com
Iovance Biotherapeutics Inc. Building a Base Near SupportSwing Trade Entry Alert Analysis - beatles.ru
What moving averages say about Iovance Biotherapeutics Inc.Real Time Growth Signal with Smart Setup - Newser
Day 5 of Loss Streak for Iovance Biotherapeutics Stock with -33% Return (vs. -64% YTD) [7/30/2025] - Trefis
Market Shock Waves: Iovance Biotherapeutics’ Sudden Challenges - timothysykes.com
Iovance Biotherapeutics Faces Market Challenges Amid Financial Setbacks - StocksToTrade
Is Iovance Biotherapeutics Stock Due for a Big Rally? - Mitrade
Using AI based signals to follow Iovance Biotherapeutics Inc.Chart Pattern Recognition for Profit Timing - Newser
Can Iovance Biotherapeutics Inc. rally from current levelsShort-Term Profit Alert With Entry Forecast - newser.com
How to monitor Iovance Biotherapeutics Inc. with trend dashboardsReliable Setup Screener with Low Risk - Newser
Is Iovance Biotherapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideFree Optimized Watchlist With Daily Adjustments - Newser
Published on: 2025-07-29 18:47:39 - beatles.ru
Why Iovance Biotherapeutics Inc. stock attracts strong analyst attentionReal Time Trade Execution Alert Plan - Newser
Iovance Biotherapeutics Inc. Company Revenue and Profit Trends: A Deep DiveWatchlist for Low Risk High Return Stocks Updated - metal.it
Price momentum metrics for Iovance Biotherapeutics Inc. explainedMomentum Prediction Based on AI Backtesting - Newser
Is Iovance Biotherapeutics a Buy on the Dip? Assessing the Risk/Reward of Autologous Cell Therapy Commercialization - AInvest
Iovance Biotherapeutics shares rise 2.03% premarket after UK's MHRA approves Tofersen for rare motor neurone disease. - AInvest
This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy? - Yahoo Finance
Iovance Biotherapeutics’ SWOT analysis: stock faces challenges amid promising data - Investing.com
What are the technical indicators suggesting about Iovance Biotherapeutics Inc.Turbocharged investment results - jammulinksnews.com
Does Iovance Biotherapeutics Inc. stock perform well during market downturnsRecord-breaking capital gains - jammulinksnews.com
How Iovance Biotherapeutics Inc. stock performs during market volatilitySwing Entry Risk Mitigation with Chart Analysis - Newser
What are analysts’ price targets for Iovance Biotherapeutics Inc. in the next 12 monthsSkyrocketing profit margins - jammulinksnews.com
Is Iovance Biotherapeutics Inc. Stock a Good Fit for Conservative InvestorsDaily Top Gainers - metal.it
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Acquired by Bank of New York Mellon Corp - Defense World
Levi & Korsinsky Notifies Shareholders of Iovance Biotherapeutics, Inc.(IOVA) of a Class Action Lawsuit and an Upcoming Deadline - Kilgore News Herald
Iovance Biotherapeutics Plummets Amidst Lawsuit and Executive Shake-up - timothysykes.com
Decoding Iovance Biotherapeutics: A TIL Breakout or Premature Optimism? - AInvest
Iovance Biotherapeutics Is Waking UpPrice Action Screams Breakout, But Fundamentals Demand Patience - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Held Back By Insufficient Growth Even After Shares Climb 75% - 富途牛牛
Iovance Biotherapeutics Soars 13.37% on FDA Approval, Buy Rating - AInvest
What analysts say about Iovance Biotherapeutics Inc. stockUnprecedented market success - PrintWeekIndia
Iovance Biotherapeutics shares rise 5.47% premarket after Pfizer's $1.25 billion licensing agreement for cancer drug. - AInvest
Iovance Biotherapeutics to Host Second Quarter and First - GlobeNewswire
About Us - FinancialContent
Goldman Sachs Downgrade Sends Iovance Biotherapeutics Tumbling - timothysykes.com
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):